BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21627048)

  • 21. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.
    Eglen RM; Reisine T
    J Biomol Screen; 2011 Dec; 16(10):1137-52. PubMed ID: 22002420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation as a target of epigenetic therapeutics in cancer.
    Li KK; Li F; Li QS; Yang K; Jin B
    Anticancer Agents Med Chem; 2013 Feb; 13(2):242-7. PubMed ID: 22934696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL).
    Kn H; Bassal S; Tikellis C; El-Osta A
    Cancer Biol Ther; 2004 Oct; 3(10):989-94. PubMed ID: 15467427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of anti-viral responses in intestinal epithelial cells by epigenetic modifying drugs is mediated by a reduction in viral pattern recognition receptor expression and activity.
    Hennessy C; O'Connell S; Egan LJ; McKernan DP
    Immunopharmacol Immunotoxicol; 2019 Oct; 41(5):527-537. PubMed ID: 31505962
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases.
    Fandy TE
    Curr Med Chem; 2009; 16(17):2075-85. PubMed ID: 19519382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
    Oh S; Ko JY; Oh C; Yoo KH
    Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
    Falkenberg KJ; Johnstone RW
    Nat Rev Drug Discov; 2014 Sep; 13(9):673-91. PubMed ID: 25131830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The promise and failures of epigenetic therapies for cancer treatment.
    Bojang P; Ramos KS
    Cancer Treat Rev; 2014 Feb; 40(1):153-69. PubMed ID: 23831234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
    Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
    Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H3K9 trimethylation precedes DNA methylation during sheep oogenesis: HDAC1, SUV39H1, G9a, HP1, and Dnmts are involved in these epigenetic events.
    Russo V; Bernabò N; Di Giacinto O; Martelli A; Mauro A; Berardinelli P; Curini V; Nardinocchi D; Mattioli M; Barboni B
    J Histochem Cytochem; 2013 Jan; 61(1):75-89. PubMed ID: 23019017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.
    Ye CG; Chen GG; Ho RLK; Merchant JL; He ML; Lai PBS
    Biochim Biophys Acta; 2013 Dec; 1833(12):2970-2979. PubMed ID: 23954442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenomes as therapeutic targets.
    Hamm CA; Costa FF
    Pharmacol Ther; 2015 Jul; 151():72-86. PubMed ID: 25797698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [DNA methyltransferase inhibitors * histone deacetylase inhibitors].
    Kikuchi J; Furukawa Y
    Nihon Rinsho; 2014 Jun; 72(6):1136-42. PubMed ID: 25016817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging epigenetic targets and therapies in cancer medicine.
    Popovic R; Licht JD
    Cancer Discov; 2012 May; 2(5):405-13. PubMed ID: 22588878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation.
    Peng Z; Zhou W; Zhang C; Liu H; Zhang Y
    Med Sci Monit; 2018 Jan; 24():461-472. PubMed ID: 29363667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression pattern of DNA-methyltransferases and its health implication (short review).
    Kvaratskhelia E; Tkemaladze T; Abzianidze E
    Georgian Med News; 2014 Mar; (228):76-81. PubMed ID: 24743128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure.
    Ghoshal K; Datta J; Majumder S; Bai S; Dong X; Parthun M; Jacob ST
    Mol Cell Biol; 2002 Dec; 22(23):8302-19. PubMed ID: 12417732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemical Tools with Fluorescence Switches for Verifying Epigenetic Modifications.
    Hori Y; Kikuchi K
    Acc Chem Res; 2019 Oct; 52(10):2849-2857. PubMed ID: 31577127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.
    Mohammad HP; Barbash O; Creasy CL
    Nat Med; 2019 Mar; 25(3):403-418. PubMed ID: 30842676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA methyltransferase 1(DNMT1) induced the expression of suppressors of cytokine signaling3 (Socs3) in a mouse model of asthma.
    Verma M; Chattopadhyay BD; Kumar S; Kumar K; Verma D
    Mol Biol Rep; 2014 Jul; 41(7):4413-24. PubMed ID: 24599782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.